Clinical Trial

Vancomycin in TKAs

Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
Periprosthetic joint infection (PJI) is a national health crisis and leads to very poor outcomes for patients undergoing elective joint replacement. Within the realm of elective total knee arthroplasty (TKA), various methods of infection prophylaxis are in place. These include sterile precautions, would/tissue handling, and antibiotic prophylaxis. With respect to the latter, various approaches have been utilized including intravenous and intraosseous administration of vancomycin, preoperatively. Intraosseous administration does require another wound and a specific device to administer. The investigators proposed that intraarticular injection of vancomycin is non-inferior to intraosseous administration, thus reducing wounds, time, and cost.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-12-05.
Trial Details
NCT Number NCT07282782
Lead Sponsor University of California, San Diego
Conditions Total Knee Arthroplasty
Enrollment 30 participants
Start Date 2024-06-10
Primary Completion 2026-12-31 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-03